Back to News
Market Impact: 0.15
Cytek BioSciences Inc Reaches Analyst Target Price
Source: Nasdaq
Analyst EstimatesAnalyst InsightsMarket Technicals & FlowsHealthcare & Biotech
Cytek BioSciences shares traded at $5.71, exceeding the average 12-month analyst price target of $5.56 by $0.15, or approximately 2.7%. The move above consensus target levels could prompt analysts to reassess their ratings or target prices, but the article provides no new operating, earnings, or guidance information.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.15
Ticker Sentiment
CTKB0.20
More News
- Cathie Wood 'always feels better when the market is worried' — here's why
- Street Calls of The Week
- AI stock selloff drives investors to China, India, and overlooked Asian sectors
- Decisive election. Dramatic stock swings. How we handled the market last week
- Berkshire Hathaway more than doubles buybacks in third quarter as earnings decline
- Berkshire Hathaway stock is a haven again as investors flee AI bloodbath while its own portfolio takes a hit amid reshuffling